| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3283155 | Clinical Gastroenterology and Hepatology | 2012 | 6 Pages |
Abstract
On the basis of data from 1 year of SONIC, the combination of IFX/AZA was more effective than IFX alone in patients with Crohn's disease who are naïve to either drug. For the risks of combination therapy to outweigh the benefits in this time frame, the incidence of serious adverse events would have to be higher than seems clinically realistic.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Corey A. Siegel, Samuel R.G. Finlayson, Bruce E. Sands, Anna N.A. Tosteson,